Efficacy of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of salmeterol/fluticasone (SAL/FLU) & tiotropium (TIO) in patients with uncontrolled asthma on prior LABA/ICS high-dose (GINA step 5): Results from ARGON study
Conclusion: In patients uncontrolled on LABA/ICS high-dose, efficacy of single inhaler IND/GLY/MF (high- and medium-dose) o.d. was similar to SAL/FLU high-dose b.i.d. & TIO o.d. via two different inhalers with two different dosing regimens, suggestive of potential clinical benefit of this treatment option over the current standard of care. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Gessner, C., Lawrence, D., Mezzi, K., Brittain, D., Van-Zyl Smit, R. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
Efficacy of once-daily (o.d.) indacaterol/glycopyrronium/mometasone (IND/GLY/MF) vs free combination of twice-daily salmeterol/fluticasone (SAL/FLU) & o.d. tiotropium with respect to age, age at asthma-onset & BMI at baseline: ARGON subgroup analysis
Conclusion: The patient characteristics analysed (age, age of asthma onset & BMI) do not significantly impact positive outcomes when using single inhaler o.d. IND/GLY/MF vs free combination of twice daily (b.i.d.) SAL/FLU & o.d. TIO. Therefore, treatment personalisation in terms of patient preference (e.g., convenience of o.d. vs b.i.d. regimen, single inhaler, device type) would be more appropriate. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Van Zyl-Smit, R., Lawrence, D., Mezzi, K., Brittain, D., Jaumont, X., Gessner, C. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
Ventilation and tissue oxygenation patterns induced by LABA and LAMA in COPD patients
Conclusions: In our cohort of COPD patients, LABA induced greater proximal bronchodilation than LAMA. Despite the opposite gradient of their documented receptor density, both drugs caused a similar peripheral obstruction relief which resulted in an increased tissue oxygenation after LAMA only. Our data suggest that this could be associated to an improvement in the pulmonary capillary vascularization induced by LAMA. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Perez Bogerd, S., Van Muylem, A., Maufroy, E., El.Khloufi, Y., Zengin, S., Faoro, V., Malinovschi, A., Michils, A. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
A novel chronic guinea pig model of COPD using LPS and poly(I:C) exposure
Conclusion: A novel chronic model of COPD was implemented using 12 weeks, twice weekly exposure to LPS and poly(I:C). The model is characterized by airway fibrosis, septal thickening and possibly right ventricle hypertrophy. The effect on inflammation was reversed by tiotropium in the validation study. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: De Looff, M., Verschut, V., Woest, M. E., Gorter, I. C., Belfor, K. S., Bos, I. S. T., De Jager, M. H., Gosens, R., Villetti, G., Facchinetti, F., Kistemaker, L. E. M. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
IL-4 levels in sputum correlate with increased mucus production and ciliary dysfunction
Dysfunctional mucociliary clearance is a key feature of several chronic respiratory diseases (Bronchiectasis, COPD, Severe Asthma and CF). IL-4 is a Th2 associated pro-inflammatory cytokine. Anti-IL-4 therapies such as dupilumab are used in severe asthma and in phase 2 trials in COPD. We have recently reported an IL-4 driven endotype in bronchiectasis.The relationships between sputum IL-4, mucus properties (rheology and mass spectrometry) and ciliary function (high speed video microscopy) were investigated. Patients with asthma (n=52), COPD (n=50), CF (n=16), bronchiectasis (n=31) and smokers (n=11) were included...
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Cant, E., Bottier, M., Shuttleworth, M., Daudvohra, F., Urquhart, R. J., Gilmour, A., Crichton, M. L., Cassidy, D., Burgoyne, T., Hogg, C., Huang, J. T. J., Chalmers, J. D., Shoemark, A. Tags: 10.01 - Respiratory infections and bronchiectasis Source Type: research
Rescue medication use in patients with chronic obstructive pulmonary disease receiving umeclidinium/vilanterol versus tiotropium bromide/olodaterol in England
Conclusions: Newly prescribed UMEC/VI was superior to TIO/OLO on rescue medication use in patients with COPD in England.Funding: GSK (study 217815) (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Requena, G., Czira, A., Banks, V., Wood, R., Tritton, T., Castillo, C., Yeap, J., Wild, R., Compton, C., Duarte, M., Rothnie, K., Ismaila, A. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
EVELUT(R): dyspnoea and symptom burden in COPD patients switching from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
Conclusion: As per GOLD recommendations, dyspnoeic patients on LABA/ICS without an indication to continue ICS can be switched to T/O LAMA/LABA, with TT showing no benefit versus T/O with regards to symptoms and health status. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Buhl, R., Dreher, M., Mattiucci-Guehlke, M., Eckhardt, S., Taube, C., Vogelmeier, C., Buhl, R. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
How does Arg16Gly polymorphism affect pulmonary function and treatment response in COPD patients?
Conclusions: Arg16Gly polymorphism of ADRB2 gene is affecting PFT in COPD patients. Arg16Arg is linked tolower FVC at all visitsy. Treatment response to LAMA/LABA combination was comparable in all groups, but mathematic model revealed different pattern in Arg16Arg genotype, which indicate tachyphylaxis of ADRB2 receptor. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Slepchenko, N., Mostovoy, Y., Dmytriiev, K., Smereka, Y., Dmytriiev, D. Tags: 05.01 - Airway pharmacology and treatment Source Type: research
TRONARTO post hoc analysis: factors affecting peak inspiratory flow (PIF) variability
Conclusion: Age, sex, and stature did not show a significant trend with PIF variability. PIF variability, in both daily at-home measurements, and between in-clinic and at-home measurements, reduced over 4 weeks. (Source: European Respiratory Journal)
Source: European Respiratory Journal - December 1, 2022 Category: Respiratory Medicine Authors: Mahler, D. A., Watz, H., Emerson-Stadler, R., Ritz, J., Shaikh, A., Drummond, M. B. Tags: 05.02 - Monitoring airway disease Source Type: research
Comparison of Clinical Outcomes among Different Fixed-dose Combinations of Long-acting Muscarinic Antagonists and Long-acting β < sub > 2 < /sub > -agonists (LAMA/LABA) in Patients with Chronic Obstructive Pulmonary Disease
Chest. 2022 Nov 26:S0012-3692(22)04197-6. doi: 10.1016/j.chest.2022.11.027. Online ahead of print.ABSTRACTBACKGROUND: Researchers have yet to obtain conclusive evidence differentiating among fixed-dose combinations (FDCs) of long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs) for chronic obstructive pulmonary disease (COPD) in terms of real-world clinical outcomes.RESEARCH QUESTION: What are the differences between available LAMA/LABA FDCs on the risk of acute exacerbation and cardiovascular events?STUDY DESIGN AND METHODS: This retrospective cohort study based on a national insurance claims da...
Source: Chest - November 28, 2022 Category: Respiratory Medicine Authors: Ching-Fu Weng Chien-Chih Wu Mei-Hsuan Wu Fang-Ju Lin Source Type: research
Comparison of Clinical Outcomes among Different Fixed-dose Combinations of Long-acting Muscarinic Antagonists and Long-acting β < sub > 2 < /sub > -agonists (LAMA/LABA) in Patients with Chronic Obstructive Pulmonary Disease
Chest. 2022 Nov 26:S0012-3692(22)04197-6. doi: 10.1016/j.chest.2022.11.027. Online ahead of print.ABSTRACTBACKGROUND: Researchers have yet to obtain conclusive evidence differentiating among fixed-dose combinations (FDCs) of long-acting muscarinic antagonists (LAMAs) and long-acting beta-agonists (LABAs) for chronic obstructive pulmonary disease (COPD) in terms of real-world clinical outcomes.RESEARCH QUESTION: What are the differences between available LAMA/LABA FDCs on the risk of acute exacerbation and cardiovascular events?STUDY DESIGN AND METHODS: This retrospective cohort study based on a national insurance claims da...
Source: Chest - November 28, 2022 Category: Respiratory Medicine Authors: Ching-Fu Weng Chien-Chih Wu Mei-Hsuan Wu Fang-Ju Lin Source Type: research
Regulation and directed inhibition of ECP production by human neutrophils
ConclusionsOur results suggest the molecular pathways involved in ECP production and potential therapeutic targets. We also provide a new method to evaluate disease severity in asthmatic patients based on the quantification of in vitro ECP production by peripheral neutrophils. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - November 28, 2022 Category: Allergy & Immunology Source Type: research
Antagonism of m3 Alleviates Type 2 Inflammation in Allergic Rhinitis Mice
CONCLUSION: Antagonism of m3 alleviated type 2 inflammation in the nasal mucosa of AR mice.PMID:36343939 | DOI:10.1177/19458924221137977 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - November 7, 2022 Category: ENT & OMF Authors: Yu Chen Aijie Huang Guolin Tan Honghui Liu Source Type: research
Antagonism of m3 Alleviates Type 2 Inflammation in Allergic Rhinitis Mice
CONCLUSION: Antagonism of m3 alleviated type 2 inflammation in the nasal mucosa of AR mice.PMID:36343939 | DOI:10.1177/19458924221137977 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - November 7, 2022 Category: ENT & OMF Authors: Yu Chen Aijie Huang Guolin Tan Honghui Liu Source Type: research
Antagonism of m3 Alleviates Type 2 Inflammation in Allergic Rhinitis Mice
CONCLUSION: Antagonism of m3 alleviated type 2 inflammation in the nasal mucosa of AR mice.PMID:36343939 | DOI:10.1177/19458924221137977 (Source: American Journal of Rhinology and Allergy)
Source: American Journal of Rhinology and Allergy - November 7, 2022 Category: ENT & OMF Authors: Yu Chen Aijie Huang Guolin Tan Honghui Liu Source Type: research
